166 related articles for article (PubMed ID: 19231005)
21. IL28B polymorphism, pretreatment CXCL10, and HCV RNA levels predict treatment response in racially diverse HIV/HCV coinfected and HCV monoinfected patients.
Zeremski M; Dimova RB; Makeyeva J; Sipley JD; Jacobson IM; Rennert H; Talal AH
J Acquir Immune Defic Syndr; 2013 May; 63(1):9-16. PubMed ID: 23274935
[TBL] [Abstract][Full Text] [Related]
22. Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection.
Rodriguez-Torres M; Lawitz E; Yangco B; Jeffers L; Han SH; Thuluvath PJ; Rustgi V; Harrison S; Ghalib R; Vierling JM; Luketic V; Zamor PJ; Ravendhran N; Morgan TR; Pearlman B; O'Brien C; Khallafi H; Pyrsopoulos N; Kong G; McPhee F; Yin PD; Hughes E; Treitel M
Ann Hepatol; 2016 Nov-Dec 2016; 15(6):834-845. PubMed ID: 27740516
[TBL] [Abstract][Full Text] [Related]
23. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.
Conjeevaram HS; Fried MW; Jeffers LJ; Terrault NA; Wiley-Lucas TE; Afdhal N; Brown RS; Belle SH; Hoofnagle JH; Kleiner DE; Howell CD;
Gastroenterology; 2006 Aug; 131(2):470-7. PubMed ID: 16890601
[TBL] [Abstract][Full Text] [Related]
24. Altered expression of interferon-stimulated genes is strongly associated with therapeutic outcomes in hepatitis B virus infection.
Han M; Li Y; Wu W; Zhang Y; Yan W; Luo X; Ning Q
Antiviral Res; 2017 Nov; 147():75-85. PubMed ID: 28988797
[TBL] [Abstract][Full Text] [Related]
25. Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1.
Howell CD; Gorden A; Ryan KA; Thompson AJ; Ibrahim C; Fried M; Afdhal NH; McHutchison JG; Shianna KV; Goldstein DB; Shuldiner AR; Mitchell BD
J Hepatol; 2012 Mar; 56(3):557-63. PubMed ID: 22027585
[TBL] [Abstract][Full Text] [Related]
26. Usefulness of viral kinetics for early prediction of a sustained virological response in HCV-1 non-responders re-treated with pegylated interferon and ribavirin.
Deltenre P; Corouge M; Canva V; Castel H; Wartel F; Dharancy S; Louvet A; Lazrek M; Moreno C; Henrion J; Mathurin P
J Hepatol; 2011 Nov; 55(5):989-95. PubMed ID: 21354445
[TBL] [Abstract][Full Text] [Related]
27. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection.
Foster GR; Pianko S; Brown A; Forton D; Nahass RG; George J; Barnes E; Brainard DM; Massetto B; Lin M; Han B; McHutchison JG; Subramanian GM; Cooper C; Agarwal K;
Gastroenterology; 2015 Nov; 149(6):1462-70. PubMed ID: 26248087
[TBL] [Abstract][Full Text] [Related]
29. HCV virological response during treatment of chronic hepatitis C is associated with liver histological improvement in patients with HCV/HIV co-infection.
Castro G; Ramalho LN; Zucoloto S; Martinelli Ade L; Figueiredo JF
Braz J Infect Dis; 2008 Jun; 12(3):180-5. PubMed ID: 18833400
[TBL] [Abstract][Full Text] [Related]
30. Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.
Jabłonowska E; Piekarska A; Koślińska-Berkan E; Omulecka A; Szymańska B; Wójcik K
Acta Biochim Pol; 2012; 59(3):333-7. PubMed ID: 22924160
[TBL] [Abstract][Full Text] [Related]
31. Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus.
Pineda JA; Caruz A; Rivero A; Neukam K; Salas I; Camacho A; Palomares JC; Mira JA; Martínez A; Roldán C; de la Torre J; Macías J
Clin Infect Dis; 2010 Oct; 51(7):788-95. PubMed ID: 20804372
[TBL] [Abstract][Full Text] [Related]
32. IL28B and interferon-gamma inducible protein 10 for prediction of rapid virologic response and sustained virologic response in HIV-HCV-coinfected patients.
Payer BA; Reiberger T; Aberle J; Ferenci P; Holzmann H; Rieger A; Peck-Radosavljevic M;
Eur J Clin Invest; 2012 Jun; 42(6):599-606. PubMed ID: 22117591
[TBL] [Abstract][Full Text] [Related]
33. Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load.
Neukam K; Camacho A; Caruz A; Rallón N; Torres-Cornejo A; Rockstroh JK; Macías J; Rivero A; Benito JM; López-Cortés LF; Nattermann J; Gómez-Mateos J; Soriano V; Pineda JA
J Hepatol; 2012 Apr; 56(4):788-94. PubMed ID: 22173157
[TBL] [Abstract][Full Text] [Related]
34. Peripheral blood mononuclear cells microRNA predicts treatment outcome of hepatitis C virus genotype 1 infection.
Hsi E; Huang CF; Dai CY; Juo SH; Chou WW; Huang JF; Yeh ML; Lin ZY; Chen SC; Wang LY; Chuang WL; Yu ML
Antiviral Res; 2014 May; 105():135-42. PubMed ID: 24637254
[TBL] [Abstract][Full Text] [Related]
35. Analysis of sequences of hepatitis C virus NS5A genotype 1 in HIV-coinfected patients with a null response to nitazoxanide or peg-interferon plus ribavirin.
Sede M; Laufer N; Ojeda D; Gun A; Cahn P; Quarleri J
Arch Virol; 2013 Sep; 158(9):1907-15. PubMed ID: 23553458
[TBL] [Abstract][Full Text] [Related]
36. Viral and host factors in the prediction of response to interferon-alpha therapy in chronic hepatitis C after long-term follow-up.
Knolle PA; Kremp S; Höhler T; Krummenauer F; Schirmacher P; Gerken G
J Viral Hepat; 1998 Nov; 5(6):399-406. PubMed ID: 9857349
[TBL] [Abstract][Full Text] [Related]
37. Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin.
Bonardi R; Tabone M; Manca A; Pellicano R; Ciancio A; Rizzetto M
Biomed Pharmacother; 2011 Jul; 65(4):303-6. PubMed ID: 21723079
[TBL] [Abstract][Full Text] [Related]
38. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors.
Shirakawa H; Matsumoto A; Joshita S; Komatsu M; Tanaka N; Umemura T; Ichijo T; Yoshizawa K; Kiyosawa K; Tanaka E;
Hepatology; 2008 Dec; 48(6):1753-60. PubMed ID: 18925643
[TBL] [Abstract][Full Text] [Related]
39. Early changes in hepatitis C virus (HCV) levels in response to peginterferon and ribavirin treatment in patients with chronic HCV genotype 1 infection.
Hoofnagle JH; Wahed AS; Brown RS; Howell CD; Belle SH;
J Infect Dis; 2009 Apr; 199(8):1112-20. PubMed ID: 19284286
[TBL] [Abstract][Full Text] [Related]
40. Treatment of hepatitis C in HCV mono-infected and in HIV-HCV co-infected patients: an open-labelled comparison study.
Gonvers JJ; Heim MH; Cavassini M; Müllhaupt B; Genné D; Bernasconi E; Borovicka J; Cerny A; Chave JP; Chuard C; Dufour F; Dutoit V; Malinverni R; Monnat M; Negro F; Troilliet N; Oneta C
Swiss Med Wkly; 2010; 140():w13055. PubMed ID: 20648398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
